Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

Under a new licensing pact, Synaffix will grant Boehringer Ingelheim access to its bespoke ADC technologies for an "agreed but undisclosed number of targets." The first target was decided by the ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

In Shark Tank India Season 4, Ritesh Agarwal shared his past rejection by Kunal Bahl, inspiring the audience with his perseverance. Pooja Balani and Narpat Singh Rathore pitched their cheesecake ...

Meanwhile, Ritesh and Namita demonstrated flexibility in their offers. Ultimately, Rohan decided to partner with Ritesh Agarwal, leveraging his deep connections in the travel industry. The final ...

Ritesh Agarwal, founder and group CEO of OYO Rooms, on Tuesday night revealed the most booked hill stations for New Year 2025 celebrations. As per the OYO Rooms founder, the locations that are ...

Ritesh International Limited is an India-based company, which is engaged in the business of manufacturing and selling stearic acid, fatty acids, glycerin and readymade garments. The Company is ...